copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Home - Curis, Inc At Curis, we are developing differentiated therapeutics with the goal of improving the lives of cancer patients Our new animation shows how Emavusertib (CA-4948) is being developed to target hematologic malignancies and other cancers
Pipeline Overview - Curis, Inc We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer * IP licensed from Aurigene ** IP licensed to Aurigene *** IP licensed to Genentech Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development
Company Overview - Curis, Inc At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer
Emavusertib (CA-4948) - Curis, Inc As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally-available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948)
About - Curis, Inc We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer Our clinical stage drug candidates are:
Partner Collaborations - Curis, Inc Curis’ collaborator Aurigene is one of the first companies to target inhibitory immune checkpoints using synthetic small molecule compounds that can be administered orally and result in potent immune-mediated anti-tumor activity thus far in the preclinical setting
Ahmed Hamdy, MBBCH - Curis, Inc Dr Hamdy is Chief Medical Officer of Curis, joining the Company in May 2025 Prior to joining Curis, he served as CEO and Chairman of the board of directors of Vincerx Pharma, Inc Prior to Vincerx, Dr Hamdy co-founded Acerta Pharma, LLC, and served as its CEO and CMO